NCT07253038 Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
| NCT ID | NCT07253038 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Huntington Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-12-01 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the usefulness of a test of social functioning in persons with Huntington disease. Huntington disease affects motor function, psychological well-being and cognitive functions ("thinking abilities" such as paying attention, remembering and solving problems). It is also believed to affect important social functions, including the ability to understand others' intentions and emotions (social cognition). The test of interest in this study is called The Double Movie for the Assessment of Social Cognition-Multiple Choice (DMASC-MC) and will be compared to two other similar and well-known tests. The main question which the study aims to answer is: • Is DMASC-MC a useful tool for detecting problems with social functioning in adult persons with early Huntington disease? In the study, participants will meet with a medical doctor and a psychologist for assessment of different symptoms related to Huntington disease, including social functioning. Better methods for identifying problems with social functioning could help persons with Huntington disease and their families in mainly two ways. Firstly, it could increase their understanding of how the disease has affected them. Secondly, a better understanding of these problems could lead to better recommendations and interventions from medical teams, which would also benefit persons with Huntington disease and families.
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for persons with HD 1. Clinical diagnosis of HD 2. CAG repeat: 40 and more Inclusion criteria for control group 1\. No heritage of HD or negative pre-symptomatic HD gene test Exclusion Criteria: Participants in both groups are excluded from the study if any of the following criteria apply: 1. Dementia or MOCA\<19, The Mini Mental State Examination (MMSE) \<19 2. Other neurological disorders 3. Ongoing psychosis 4. Ongoing alcohol/drug addiction 5. Other native language than Swedish 6. Severe problems with vision and hearing
Contact & Investigator
Asa Petersen, MD PhD
PRINCIPAL INVESTIGATOR
Department of Psychiatry, Skåne University Hospital
Frequently Asked Questions
Who can join the NCT07253038 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07253038 currently recruiting?
Yes, NCT07253038 is actively recruiting participants. Contact the research team at asa.petersen@med.lu.se for enrollment information.
Where is the NCT07253038 trial being conducted?
This trial is being conducted at Lund, Sweden.
Who is sponsoring the NCT07253038 clinical trial?
NCT07253038 is sponsored by Region Skane. The principal investigator is Asa Petersen, MD PhD at Department of Psychiatry, Skåne University Hospital. The trial plans to enroll 40 participants.